DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for nephrogenic diabetes insipidus — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNephrogenic diabetes insipidus maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDesmopressinVasopressin receptor agonist
Structures already discussed alongside nephrogenic diabetes insipidus in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
arginine vasopressin receptor 2 (AVPR2) — AVPR2 is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has cholesterol bound in it, shown as sticks.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7DW9 · 2.6 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided concern central or cranial diabetes insipidus, not nephrogenic diabetes insipidus. One 1977 clinical study of three patients with established cranial diabetes insipidus found that a single intranasal dose of 20 micrograms of DDAVP (desmopressin) produced an antidiuretic action lasting 16 to 24 hours, and that 10 micrograms given twice daily controlled the condition with no reported side effects. All three patients preferred this to their previous treatment. A 2006 review describes desmopressin as a synthetic V2 receptor agonist with greater antidiuretic activity but lower pressor effects than natural vasopressin, and notes its use in diagnosing and treating cranial diabetes insipidus. A 2023 case report on idiopathic partial central diabetes insipidus only distinguishes central from nephrogenic forms by the site of the defect, without presenting any treatment data for the nephrogenic type.
No abstract in this set reports any drug tested or used in nephrogenic diabetes insipidus. The distinction made in the 2023 report is that nephrogenic diabetes insipidus involves resistance to antidiuretic hormone action in the renal tubules, whereas central disease involves hormone deficiency. Desmopressin, being a V2 agonist, would act on the same receptor that is defective in most congenital nephrogenic forms, but none of the provided abstracts address that scenario. There are no response rates, survival figures, or sample sizes beyond the three patients in the 1977 study, and no evidence of efficacy for any intervention in nephrogenic disease.
The evidence base here is therefore not applicable to the stated disease. What is missing is any clinical trial or case series involving patients with nephrogenic diabetes insipidus, any data on alternative agents such as thiazide diuretics or amiloride, and any stratification by genetic cause of the receptor defect. Without such studies, no conclusion can be drawn about drug repurposing for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Einstein (São Paulo) · 2023 · 2 citations · open access
Idiopathic partial central diabetes insipidus
AbstractDiabetes insipidus is a rare disorder characterized by the inability to concentrate urine, which results in hypotonic urine and increased urinary volume. It may occur because of antidiuretic hormone deficiency or resistance to its action in the renal tubules. When there is a deficiency in the synthesis of antidiuretic hormones, diabetes insipidus is called central; when there is resistance to its action in the renal tubules, it is said to be nephrogenic. We report a case of idiopathic partial central diabetes insipidus and highlight the management and treatment of the disease.
The Medical Journal of Australia · 1977 · 2 citations
DDAVP IN THE TREATMENT OF DIABETES INSIPIDUS: A CLINICAL STUDY
AbstractIn three cases of established cranial diabetes insipidus, the effectiveness of the new vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP) in controlling diabetes insipidus is demonstrated. A single dose of 20 micrograms of DDAVP given intranasally had an antidiuretic action from 16 to 24 hours in the three cases, and 10 micrograms given twice daily intranasally was effective in controlling the diabetes insipidus with no side effects. All the patients preferred this form of therapy to their previous treatment.
AbstractABSTRACT Diabetes insipidus is a rare disorder characterized by the inability to concentrate urine, which results in hypotonic urine and increased urinary volume. It may occur because of antidiuretic hormone deficiency or resistance to its action in the renal tubules. When there is a deficiency in the synthesis of antidiuretic hormones, diabetes insipidus is called central; when there is resistance to its action in the renal tubules, it is said to be nephrogenic. We report a case of idiopathic partial central diabetes insipidus and highlight the management and treatment of the disease.
Desmopressin acetate for enuresis and diabetes insipidus
AbstractDesmopressin is a synthetic agonist of the natural pituitary hormone vasopressin acetate, with enhanced antidiuretic properties. In fact, owing to its selectivity for the V2 receptor, it has a greater antidiuretic activity, but lower pressure effects compared with natural antidiuretic hormone. Desmopressin is used in the diagnosis and treatment of cranial diabetes insipidus, in the treatment of monosymptomatic enuresis and for tests of renal function.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
